SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

Search

Almirall SA

Chiusa

SettoreSettore sanitario

12.68 -1.25

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.62

Massimo

12.7

Metriche Chiave

By Trading Economics

Entrata

-1.4M

20M

Vendite

287M

548M

P/E

Media del settore

58.364

60.328

Rendimento da dividendi

1.49

Margine di Profitto

3.575

Dipendenti

2,108

EBITDA

36M

102M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.81% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.49%

2.24%

Utili prossimi

11 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

121M

2.8B

Apertura precedente

13.93

Chiusura precedente

12.68

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Almirall SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 apr 2026, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Utili

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Utili

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Utili

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisizioni, Fusioni, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Discorsi di Mercato

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Discorsi di Mercato

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Utili

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Utili

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Discorsi di Mercato

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Discorsi di Mercato

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Discorsi di Mercato
Utili

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Almirall SA Previsione

Obiettivo di Prezzo

By TipRanks

9.81% in crescita

Previsioni per 12 mesi

Media 14.1 EUR  9.81%

Alto 14.2 EUR

Basso 14 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Almirall SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.76 / 10.2Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat